LFLaura Fabbri

Laura Fabbri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Fabbri has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunotherapy-related interstitial lung disease: a call to improve risk stratification and diagnostic consistency

    by Laura Fabbri, Katerina Antoniou, Torsten Gerriet Blum, Philippe Camus, Aurélie Cazes, Joanna Chorostowska-Wynimko, Pierre Foidart, Georgia Hardavella, Marjolein A. Heuvelmans, Theodoros Karampitsakos, et al.

    Extract Immune checkpoint inhibitors (ICIs) are immunomodulatory monoclonal antibodies that enhance T-cell-mediated cytotoxicity and have significantly transformed the treatment and outcomes of many cancers [1]. The primary targets of checkpoint inhibition are programmed cell death receptor 1 (PD-1), its ligand programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) [2]. Shareable abstract A standardised risk assessment before initiating ICI treatment may improve early detection and management of IR-ILD. Multidisciplinary collaboration is crucial for enhancing patient safety, improving treatment outcomes and advancing research. https://bit.ly/4qAthl6

  • Open Access

    ERS Congress 2025: highlights from the Interstitial Lung Diseases Assembly

    by Johad Khoury, Aycan Yüksel, Nikoleta Bizymi, Antonio Fabozzi, Marta Garcia-Moyano, Marlies Wijsenbeek, Michael Kreuter, Laura Fabbri

    Shareable abstract A summary of the interstitial lung disease presentations and posters from the ERS 2025 meeting

  • Open Access

    Non-pharmacological Management of Fibrosing Interstitial Lung Diseases

    by Punchalee Kaenmuang, Wing-Ho Yip, Rasleen Kahai, Laura Fabbri

    Non-pharmacological interventions are integral to the multidisciplinary management of fibrosing interstitial lung diseases (ILDs), complementing pharmacological therapies by addressing functional decline, symptom burden, and quality of life. Palliative care is fundamental, offering a structured approach to symptom control—particularly dyspnea— and facilitating advance care planning. Oxygen therapy may provide symptomatic benefit in patients with resting, nocturnal, or exertional hypoxemia, though evidence remains limited and extrapolated mainly from idiopathic pulmonary fibrosis cohorts. Pulmonary rehabilitation, encompassing supervised exercise and patient education, has demonstrated short-term improvements in exercise tolerance; however, long-term effects on dyspnea and health-related quality of life are inconsistent. Nutritional status is an emerging area of interest, with data linking low body mass index and unintentional weight loss, underscoring the potential value of dietary assessment and intervention. Psychological support is critical, as ILD patients frequently experience anxiety, depression, and psychological distress. Although peer-led interventions remain under-investigated, they appear to address significant unmet needs in patient education and emotional support. Occupational therapy provides tailored strategies to maintain functional independence and manage fatigue, thereby improving daily living. Immunization against influenza, pneumococcus, and severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) is essential, given the elevated risk of infection-related morbidity and mortality. For selected patients with progressive disease refractory to medical therapy, lung transplantation offers a potential survival advantage, necessitating timely referral and evaluation. Although results are promising, evidence is still limited for some interventions and further research is warranted to establish robust, evidence-based guidelines for non-pharmacological management in fibrosing ILD.


  • Open Access

    Work–life balance as early career respiratory experts and ERS representatives: personal experiences, reflections and potential solutions for improvement

    by Mathieu Marillier, Athénaïs Boucly, Matteo Siciliano, Marjolein A. Heuvelmans, Amanda Dandanell Juul, Chiara Premuda, Susanne J.H. Vijverberg, Heleen Demeyer, Laura Fabbri, Augusta Beech, et al.

    Work–life balance is a real challenge for early career respiratory professionals striving to manage clinical responsibilities, research, teaching and professional commitments. In this collective reflection by members of the European Respiratory Society Early Career Member Committee, we openly explore our own experiences, struggles and lessons learned in the pursuit of balance. While some of us feel we have found a rhythm that works, many are still navigating fluctuating demands, blurred boundaries and long hours that spill into evenings, weekends and even holidays. Parenthood, changing roles and growing responsibilities have reshaped our priorities and tested our limits. Still, we remain deeply passionate about our work. Through honest discussion, we share personal strategies such as setting boundaries, using time-management tools and leaning on support networks, and highlight the emotional toll when the balance is lost. We also recognise that systemic change is needed: fairer compensation, cultural shifts around overwork, and structural support for young professionals. This article is both a reflection and a call to action: to take care of ourselves, to support one another and to shape a professional culture where wellbeing is valued as much as productivity. We hope our shared experiences resonate and offer encouragement to other early career respiratory professionals.

  • Open Access

    Accelerate your career: the power of the ERS interstitial lung disease mentorship programme

    by Catharina C. Moor, Laura Fabbri, Namrata Kewalramani, Karol Bączek, Nazia Chaudhuri, Heleen Demeyer, Michael Kreuter

    The European Respiratory Society (ERS) strongly promotes inclusion of early career members (ECMs) in the activities of the society. There are numerous opportunities for ECMs to get involved, such as training programmes, fellowship opportunities and active participation in the annual ERS congress including the Network EXcellence Training (NEXT) programme (https://www.ersnet.org).


  • Open Access

    ERS Congress 2024: highlights from the Interstitial Lung Diseases Assembly

    by Laura Fabbri, Malik A. Althobiani, Ioannis Tomos, Lurdes Planas-Cerezales, Marlies Wijsenbeek, Michael Kreuter, Catharina C. Moor

    The research presented at #ERSCongress 2024 offers promising strides towards improved ILD care through tailored technologies. These studies underscore the critical balance between human expertise and machine-driven solutions for effective implementation. https://bit.ly/3WAhw19.


  • Open Access

    The impact of COVID-19 infection on idiopathic pulmonary fibrosis mortality: a systematic review and meta-analysis

    by Davide Cavasin, Umberto Zanini, Laura Montelisciani, Maria Grazia Valsecchi, Laura Fabbri, Laura Antolini, Fabrizio Luppi

    COVID-19 has a negative impact on the survival of respiratory patients, especially those with interstitial lung disease. This review aims to better understand the effect of COVID-19 on patients with idiopathic pulmonary fibrosis (IPF). A systematic search of MEDLINE, PubMed, Embase, and Scopus performed from December 2019 up to July 2024 identified relevant studies. Eligibility criteria included English language, sample size ≥10 patients, COVID-19 infection, and outcome measures. Two independent reviewers assessed studies using the Newcastle-Ottawa Scale for bias and extracted data. Meta-analysis employed a random-effects model, and the Grading of Recommendations Assessment, Development and Evaluation assessed evidence quality. Outcomes considered were hospitalization, intensive care unit admission, and mortality. Of the 1541 initially identified articles, 6 high-quality studies were included. Meta-analysis revealed a 34% mortality rate [95% confidence interval (CI): 21-48%], 36% hospitalization rate (95% CI: 10-75%), and 31% intensive care unit admission rate (95% CI: 7-71%) among IPF patients with COVID-19. The certainty of evidence was low or very low due to publication bias and heterogeneity. This study underscores the elevated risk of hospitalization and death in IPF patients with COVID-19, emphasizing the vulnerability of this population. Prompt and tailored care is crucial to mitigate the impact of COVID-19 on IPF patients, necessitating proactive measures, vaccination, and comprehensive management.


  • New Evidence for SARS-CoV-2 Vaccine Boosting in Patients With Chronic Lung Diseases

    by Laura Fabbri, Stefan Cristian Stanel

  • Open Access

    Research priorities for progressive pulmonary fibrosis in the UK

    by Laura Fabbri, Anne-Marie Russell, Nazia Chaudhuri, Wendy Adams, Katherine Cowan, John Conway, Wendy Dickinson, Michael Gibbons, Simon Hart, Steve Jones, et al.

    Introduction Health research bodies recommend patient involvement and engagement in research and healthcare planning, although their implementation is not yet widespread. This deficiency extends to progressive pulmonary fibrosis (PPF), where crucial aspects remain unknown, including causal mechanisms, curative treatments and optimal symptom management. This study addresses these gaps by seeking stakeholders’ perspectives to guide research and treatment directions. Method A priority-setting partnership was established to explore stakeholders’ priorities in the diagnosis, treatment, management and care of PPF, including idiopathic pulmonary fibrosis which is the archetypal PPF. Stakeholders included people living with PPF, their carers, relatives and healthcare professionals involved in their management. Results Through an online open-ended survey, 2542 responses were collected from 638 stakeholders. Thematic analysis identified 48 specific research questions, which were then cross-referenced with academic literature to pinpoint research gaps. Following the evidence check, 44 unanswered questions were shortlisted by 834 stakeholders in a second online survey. Ultimately, a top 10 priority list was established through consensus. The prioritised research questions include (1) improved diagnosis accuracy and timing, (2) development of new treatments, (3) enhanced accuracy in primary care, (4) optimal timing for drug and non-drug interventions, (5) effective cough treatment, (6) early intervention for PPF, (7) improved survival rates, (8) symptom reduction, (9) impact of interventions on life expectancy and (10) new treatments with reduced side effects. Conclusion Stakeholders’ priorities can be summarised into five areas: early diagnosis, drug and non-drug treatments, survival and symptom management. Ideally, these topics should guide funding bodies and health policies.


  • Open Access

    Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis

    by Francesco Lombardi, Iain Stewart, Laura Fabbri, Wendy Adams, Leticia Kawano-Dourado, Christopher J Ryerson, Gisli Jenkins

    Objectives: Mycophenolate mofetil (MMF) and azathioprine (AZA) are immunomodulatory treatments in interstitial lung disease (ILD). This systematic review aimed to evaluate the efficacy of MMF or AZA on pulmonary function in ILD. Design: Population included any ILD diagnosis, intervention included MMF or AZA treatment, outcome was delta change from baseline in per cent predicted forced vital capacity (%FVC) and gas transfer (diffusion lung capacity of carbon monoxide, %DLco). The primary endpoint compared outcomes relative to placebo comparator, the secondary endpoint assessed outcomes in treated groups only. Eligibility criteria: Randomised controlled trials (RCTs) and prospective observational studies were included. No language restrictions were applied. Retrospective studies and studies with high-dose concomitant steroids were excluded. Data synthesis: The systematic search was performed on 9 May. Meta-analyses according to drug and outcome were specified with random effects, I2 evaluated heterogeneity and Grading of Recommendations, Assessment, Development and Evaluation evaluated certainty of evidence. Primary endpoint analysis was restricted to RCT design, secondary endpoint included subgroup analysis according to prospective observational or RCT design. Results: A total of 2831 publications were screened, 12 were suitable for quantitative synthesis. Three MMF RCTs were included with no significant effect on the primary endpoints (%FVC 2.94, 95% CI −4.00 to 9.88, I2=79.3%; %DLco −2.03, 95% CI −4.38 to 0.32, I2=0.0%). An overall 2.03% change from baseline in %FVC (95% CI 0.65 to 3.42, I2=0.0%) was observed in MMF, and RCT subgroup summary estimated a 4.42% change from baseline in %DLCO (95% CI 2.05 to 6.79, I2=0.0%). AZA studies were limited. All estimates were considered very low certainty evidence. Conclusions: There were limited RCTs of MMF or AZA and their benefit in ILD was of very low certainty. MMF may support preservation of pulmonary function, yet confidence in the effect was weak. To support high certainty evidence, RCTs should be designed to directly assess MMF efficacy in ILD. PROSPERO registration number: CRD42023423223.